CARIBOU BIOSCIENCES INC (CRBU) Stock Fundamental Analysis
USA - NASDAQ:CRBU - US1420381089 - Common Stock
2.365 USD
-0.1 (-4.25%)
We assign a fundamental rating of 3 out of 10 to CRBU. CRBU was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRBU as it has an excellent financial health rating, but there are worries on the profitability. CRBU is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CRBU had negative earnings in the past year.
CRBU had a negative operating cash flow in the past year.
CRBU had negative earnings in each of the past 5 years.
In the past 5 years CRBU always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -74.36%, CRBU is doing worse than 64.61% of the companies in the same industry.
CRBU has a Return On Equity (-98.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.36% | ||
| ROE | -98.87% | ||
| ROIC | N/A |
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRBU has been increased compared to 1 year ago.
CRBU has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.31, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CRBU (-2.31) is comparable to the rest of the industry.
CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.31 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
CRBU has a Current Ratio of 6.66. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.66, CRBU is in the better half of the industry, outperforming 67.23% of the companies in the same industry.
A Quick Ratio of 6.66 indicates that CRBU has no problem at all paying its short term obligations.
CRBU's Quick ratio of 6.66 is fine compared to the rest of the industry. CRBU outperforms 67.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.66 | ||
| Quick Ratio | 6.66 |
3. Growth
3.1 Past
CRBU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.06%.
Looking at the last year, CRBU shows a very negative growth in Revenue. The Revenue has decreased by -72.45% in the last year.
Measured over the past years, CRBU shows a quite strong growth in Revenue. The Revenue has been growing by 11.54% on average per year.
EPS 1Y (TTM)-28.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
Revenue 1Y (TTM)-72.45%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-23.01%
3.2 Future
Based on estimates for the next years, CRBU will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.70% on average per year.
Based on estimates for the next years, CRBU will show a very strong growth in Revenue. The Revenue will grow by 168.84% on average per year.
EPS Next Y-5.19%
EPS Next 2Y4.18%
EPS Next 3Y7.18%
EPS Next 5Y8.7%
Revenue Next Year3.18%
Revenue Next 2Y0.17%
Revenue Next 3Y4.65%
Revenue Next 5Y168.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CRBU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.18%
EPS Next 3Y7.18%
5. Dividend
5.1 Amount
No dividends for CRBU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CRBU (10/29/2025, 3:50:51 PM)
2.365
-0.1 (-4.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.43%
Inst Owner Change-0.89%
Ins Owners4.34%
Ins Owner Change0%
Market Cap220.23M
Revenue(TTM)9.12M
Net Income(TTM)-164263000
Analysts84.29
Price Target9.03 (281.82%)
Short Float %4.42%
Short Ratio3.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.16%
Min EPS beat(2)-45.06%
Max EPS beat(2)4.73%
EPS beat(4)3
Avg EPS beat(4)-3.54%
Min EPS beat(4)-45.06%
Max EPS beat(4)17.12%
EPS beat(8)5
Avg EPS beat(8)6.22%
EPS beat(12)9
Avg EPS beat(12)6.61%
EPS beat(16)11
Avg EPS beat(16)-11.75%
Revenue beat(2)2
Avg Revenue beat(2)18.95%
Min Revenue beat(2)6.09%
Max Revenue beat(2)31.82%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-35.93%
Max Revenue beat(4)31.82%
Revenue beat(8)4
Avg Revenue beat(8)75.58%
Revenue beat(12)7
Avg Revenue beat(12)53.25%
Revenue beat(16)8
Avg Revenue beat(16)34.23%
PT rev (1m)0%
PT rev (3m)-3.13%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-0.78%
EPS NY rev (1m)-0.45%
EPS NY rev (3m)-18.94%
Revenue NQ rev (1m)-1.13%
Revenue NQ rev (3m)4.32%
Revenue NY rev (1m)-1.06%
Revenue NY rev (3m)-1.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 24.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.33 | ||
| P/tB | 1.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0.1
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.36% | ||
| ROE | -98.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 56.49% | ||
| Cap/Sales | 29.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.66 | ||
| Quick Ratio | 6.66 | ||
| Altman-Z | -2.31 |
F-Score2
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)283.95%
Cap/Depr(5y)220.75%
Cap/Sales(3y)43.03%
Cap/Sales(5y)30.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
EPS Next Y-5.19%
EPS Next 2Y4.18%
EPS Next 3Y7.18%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-72.45%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-23.01%
Revenue Next Year3.18%
Revenue Next 2Y0.17%
Revenue Next 3Y4.65%
Revenue Next 5Y168.84%
EBIT growth 1Y-9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.37%
EBIT Next 3Y21.2%
EBIT Next 5YN/A
FCF growth 1Y-38.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.02%
OCF growth 3YN/A
OCF growth 5YN/A
CARIBOU BIOSCIENCES INC / CRBU FAQ
Can you provide the ChartMill fundamental rating for CARIBOU BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to CRBU.
Can you provide the valuation status for CARIBOU BIOSCIENCES INC?
ChartMill assigns a valuation rating of 0 / 10 to CARIBOU BIOSCIENCES INC (CRBU). This can be considered as Overvalued.
Can you provide the profitability details for CARIBOU BIOSCIENCES INC?
CARIBOU BIOSCIENCES INC (CRBU) has a profitability rating of 0 / 10.
Can you provide the financial health for CRBU stock?
The financial health rating of CARIBOU BIOSCIENCES INC (CRBU) is 7 / 10.
Can you provide the expected EPS growth for CRBU stock?
The Earnings per Share (EPS) of CARIBOU BIOSCIENCES INC (CRBU) is expected to decline by -5.19% in the next year.